Trial Profile
A phase II study of Nivolumab re-challenge therapy in patients with advanced non-small cell lung cancer who responded to prior PD-1/L1 inhibitors (WJOG9616L)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Jun 2022 Results published in the Clinical Cancer Research
- 26 May 2022 Results published in the Clinical Cancer Research
- 08 Oct 2021 Status changed from active, no longer recruiting to completed.